WO1998046573A1 - Derives d'acide 2-substitue carbamoylimidazolecarboxylique et inhibiteur de l'epaississement de la paroi vasculaire - Google Patents
Derives d'acide 2-substitue carbamoylimidazolecarboxylique et inhibiteur de l'epaississement de la paroi vasculaire Download PDFInfo
- Publication number
- WO1998046573A1 WO1998046573A1 PCT/JP1998/001655 JP9801655W WO9846573A1 WO 1998046573 A1 WO1998046573 A1 WO 1998046573A1 JP 9801655 W JP9801655 W JP 9801655W WO 9846573 A1 WO9846573 A1 WO 9846573A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- lower alkyl
- alkyl group
- imidazole
- lower alkoxy
- Prior art date
Links
- -1 2-substituted carbamoylimidazolecarboxylic acid Chemical class 0.000 title claims abstract description 182
- 230000008719 thickening Effects 0.000 title claims abstract description 24
- 239000003112 inhibitor Substances 0.000 title claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 169
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 45
- 150000003839 salts Chemical class 0.000 claims abstract description 41
- 125000001424 substituent group Chemical group 0.000 claims abstract description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 133
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 89
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 75
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 55
- 125000003277 amino group Chemical class 0.000 claims description 45
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 42
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 125000002723 alicyclic group Chemical group 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 27
- KYWMCFOWDYFYLV-UHFFFAOYSA-N 1h-imidazole-2-carboxylic acid Chemical class OC(=O)C1=NC=CN1 KYWMCFOWDYFYLV-UHFFFAOYSA-N 0.000 claims description 24
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 230000002792 vascular Effects 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 19
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 19
- 125000005027 hydroxyaryl group Chemical group 0.000 claims description 17
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 241001024304 Mino Species 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 42
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 239000001257 hydrogen Substances 0.000 abstract description 4
- 150000001733 carboxylic acid esters Chemical group 0.000 abstract 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 82
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- 239000000203 mixture Substances 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 25
- 239000002904 solvent Substances 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 125000006239 protecting group Chemical group 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 8
- 239000012156 elution solvent Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 229910000761 Aluminium amalgam Inorganic materials 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 208000037803 restenosis Diseases 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 5
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical class CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 3
- YTFVRYKNXDADBI-UHFFFAOYSA-M 3,4,5-trimethoxycinnamate Chemical compound COC1=CC(C=CC([O-])=O)=CC(OC)=C1OC YTFVRYKNXDADBI-UHFFFAOYSA-M 0.000 description 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- RFOFSMYXSBHWPC-UHFFFAOYSA-N 5-amino-1h-imidazole-2-carboxylic acid Chemical class NC1=CN=C(C(O)=O)N1 RFOFSMYXSBHWPC-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229960002523 mercuric chloride Drugs 0.000 description 3
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- AXBARGLGUNBQDZ-UHFFFAOYSA-N propan-2-yl 2-amino-2-cyanoacetate Chemical compound CC(C)OC(=O)C(N)C#N AXBARGLGUNBQDZ-UHFFFAOYSA-N 0.000 description 3
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 2
- JDFDHBSESGTDAL-UHFFFAOYSA-N 3-methoxypropan-1-ol Chemical compound COCCCO JDFDHBSESGTDAL-UHFFFAOYSA-N 0.000 description 2
- BWRWNUQAQPAYCK-UHFFFAOYSA-N 3-methoxypyrrolidine Chemical compound COC1CCNC1 BWRWNUQAQPAYCK-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- CNEFRTDDIMNTHC-DJWKRKHSSA-N (2z)-2-cyano-2-hydroxyiminoacetic acid Chemical compound O\N=C(\C#N)C(O)=O CNEFRTDDIMNTHC-DJWKRKHSSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- XGCDBGRZEKYHNV-UHFFFAOYSA-N 1,1-bis(diphenylphosphino)methane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CP(C=1C=CC=CC=1)C1=CC=CC=C1 XGCDBGRZEKYHNV-UHFFFAOYSA-N 0.000 description 1
- XQALCMPPZHQMLW-UHFFFAOYSA-N 1,3-diethoxypropan-1-ol Chemical compound CCOCCC(O)OCC XQALCMPPZHQMLW-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- LOKGSQPYZNBSSL-UHFFFAOYSA-N 1h-imidazol-1-ium;propanoate Chemical compound CCC([O-])=O.[NH2+]1C=CN=C1 LOKGSQPYZNBSSL-UHFFFAOYSA-N 0.000 description 1
- ZUUNZDIGHGJBAR-UHFFFAOYSA-N 1h-imidazole-2,5-dicarboxylic acid Chemical class OC(=O)C1=CNC(C(O)=O)=N1 ZUUNZDIGHGJBAR-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- LXSVWFRZICUOLU-UHFFFAOYSA-N 2-butoxypropanoic acid Chemical compound CCCCOC(C)C(O)=O LXSVWFRZICUOLU-UHFFFAOYSA-N 0.000 description 1
- MLIREBYILWEBDM-UHFFFAOYSA-M 2-cyanoacetate Chemical compound [O-]C(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-M 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 229940093475 2-ethoxyethanol Drugs 0.000 description 1
- ADDBAPLLQRBDLT-UHFFFAOYSA-N 2-ethoxyiminoacetic acid Chemical compound CCON=CC(O)=O ADDBAPLLQRBDLT-UHFFFAOYSA-N 0.000 description 1
- 125000006290 2-hydroxybenzyl group Chemical group [H]OC1=C(C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- YTFVRYKNXDADBI-SNAWJCMRSA-N 3,4,5-trimethoxycinnamic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1OC YTFVRYKNXDADBI-SNAWJCMRSA-N 0.000 description 1
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical compound O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000006291 3-hydroxybenzyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
- 125000001137 3-hydroxypropoxy group Chemical group [H]OC([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- OVWSNDOUOHKMOM-UHFFFAOYSA-N 3-phenylprop-2-enoic acid;hydrochloride Chemical compound Cl.OC(=O)C=CC1=CC=CC=C1 OVWSNDOUOHKMOM-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005977 3-phenylpropyloxy group Chemical group 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010060965 Arterial stenosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- YTFVRYKNXDADBI-UHFFFAOYSA-N O-Methylsinapic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1OC YTFVRYKNXDADBI-UHFFFAOYSA-N 0.000 description 1
- IZOQMSVDBIIWSJ-UHFFFAOYSA-N OC1CCN(CC1)C(=O)C=1NC=CN1 Chemical compound OC1CCN(CC1)C(=O)C=1NC=CN1 IZOQMSVDBIIWSJ-UHFFFAOYSA-N 0.000 description 1
- NBMDYJCJAAJDOP-UHFFFAOYSA-N ON=C(C(=O)OC(C)C)C#N Chemical compound ON=C(C(=O)OC(C)C)C#N NBMDYJCJAAJDOP-UHFFFAOYSA-N 0.000 description 1
- DLFACWDYVMGVGZ-UHFFFAOYSA-N ON=C(C(=O)OCCCOC)C#N Chemical compound ON=C(C(=O)OCCCOC)C#N DLFACWDYVMGVGZ-UHFFFAOYSA-N 0.000 description 1
- SHTJCNMXQUEJGO-UHFFFAOYSA-J O[Cr](O)(=O)=O.O[Cr](O)(=O)=O.C1=CC=NC=C1.C1=CC=NC=C1.C1=CC=NC=C1.C1=CC=NC=C1 Chemical compound O[Cr](O)(=O)=O.O[Cr](O)(=O)=O.C1=CC=NC=C1.C1=CC=NC=C1.C1=CC=NC=C1.C1=CC=NC=C1 SHTJCNMXQUEJGO-UHFFFAOYSA-J 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- PXAJQJMDEXJWFB-UHFFFAOYSA-N acetone oxime Chemical compound CC(C)=NO PXAJQJMDEXJWFB-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000005157 alkyl carboxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- HFLBBPNJTAHFEA-UHFFFAOYSA-N benzyl 2-hydroxypyrrolidine-1-carboxylate Chemical compound OC1CCCN1C(=O)OCC1=CC=CC=C1 HFLBBPNJTAHFEA-UHFFFAOYSA-N 0.000 description 1
- MBLJFGOKYTZKMH-UHFFFAOYSA-N benzyl 3-hydroxypyrrolidine-1-carboxylate Chemical compound C1C(O)CCN1C(=O)OCC1=CC=CC=C1 MBLJFGOKYTZKMH-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- RKGLUDFWIKNKMX-UHFFFAOYSA-L dilithium;sulfate;hydrate Chemical compound [Li+].[Li+].O.[O-]S([O-])(=O)=O RKGLUDFWIKNKMX-UHFFFAOYSA-L 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- DSHWMBCJDOGPTB-UHFFFAOYSA-N ethyl 2-ethoxy-2-iminoacetate Chemical compound CCOC(=N)C(=O)OCC DSHWMBCJDOGPTB-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005932 isopentyloxycarbonyl group Chemical group 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- CMCVOLORCOVKGB-UHFFFAOYSA-N methyl 2-amino-2-cyanoacetate Chemical compound COC(=O)C(N)C#N CMCVOLORCOVKGB-UHFFFAOYSA-N 0.000 description 1
- ZTUBRMAHOKWHCL-UHFFFAOYSA-N methyl 2-cyano-2-hydroxyiminoacetate Chemical compound COC(=O)C(=NO)C#N ZTUBRMAHOKWHCL-UHFFFAOYSA-N 0.000 description 1
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 1
- ANGDWNBGPBMQHW-UHFFFAOYSA-N methyl cyanoacetate Chemical compound COC(=O)CC#N ANGDWNBGPBMQHW-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005933 neopentyloxycarbonyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002923 oximes Chemical group 0.000 description 1
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005930 sec-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- the present invention relates to 2-substituted rubamoyl imidazole carboxylic acid derivatives useful as pharmaceuticals and pharmacologically acceptable salts thereof.
- Atherosclerosis progresses due to the accumulation of lipids in the blood vessel wall, cell proliferation in the intima of the blood vessel, and the accumulation of collagen, leading to thickening or occlusion of the blood vessel wall. If such a state is left unchecked, there is a danger of causing a serious situation such as angina pectoris, myocardial infarction or cerebral infarction. At present, no drug has been developed to suppress the thickening or occlusion of the blood vessel wall caused by such arteriosclerosis.
- PTCA percutaneous transluminal coronary angioplasty
- DCA directional coronary atherectomy
- the present inventors have conducted intensive studies to find a compound having an inhibitory effect on abnormal proliferation of intimal cells, and as a result, it has been found that certain 2-substituted rubamoyl imidazole carboxylate derivatives have excellent vascular properties.
- the present inventors have found that they have a smooth muscle cell proliferation inhibitory activity and the like and are useful as an agent for suppressing vascular wall thickening, and have accomplished the present invention.
- the present invention has the general formula
- R 1 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group, a lower alkoxy group, a hydroxy lower alkoxy group, a cycloalkyl lower alkoxy group, an aryl lower alkoxy group, a lower acyl group, a mono or Di-lower alkyl-substituted amino group or lower alkoxycarbonyl group;
- R 2 and R 3 may be the same or different; hydrogen atom, halogen atom, lower alkyl group, lower alkoxy group, cycloalkyl lower alkoxy group Or an aryl lower alkoxy group
- the other is a lower alkoxycarbonyl group, a mono- or di-hydroxy lower alkoxycarbonyl group, a mono- or di-lower alkoxy lower alkoxycarbonyl group, a hydroxyaryl lower alkoxycarbonyl group, a lower alkoxyaryl group.
- a lower alkoxycarbonyl group or a cycloalkyloxycarbonyl group optionally having one or more oxygen atoms in the ring wherein R 4 is a lower alkyl group, an amino lower alkyl group, a mono- or di-lower alkyl group; Substituted amino lower alkyl group, hydroxy lower alkyl group, mono- or di-lower alkoxy lower alkyl group, lower alkyl group having an alicyclic amino group which may have an oxygen atom in the ring, aryl lower alkyl group, Hydroxyl lower alkyl group, lower alkoxy A arylalkyl group or a cycloalkyl group optionally having one or more oxygen atoms in a ring, R 5 is a hydrogen atom or a lower alkyl group, R 4 and R 5 are An alicyclic amino group which may have an oxygen atom in the ring due to both force bonding and which may have a hydroxyl group, a lower alkoxy group
- the present invention relates to a vascular wall thickening inhibitor comprising a 2-substituted rubamoyl imidazole carboxylic acid derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient. .
- the present invention relates to the use of a 2-substituted rubamoyl imidazole rubonic acid derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof as a vascular wall thickening inhibitor.
- the present invention provides a 2-substituted rubamoyl imidazole carboxylic acid derivative represented by the above general formula (I) or a pharmacologically acceptable salt thereof for the manufacture of a medicament for preventing or treating vascular wall thickening.
- the present invention provides a method for preventing or treating vascular wall thickening by administering a 2-substituted rubamoyl imidazole carboxylic acid derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof. It is about.
- the present invention is characterized in that a 2-substituted rubamoylimidazole carboxylic acid derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof is used as an active ingredient of a drug.
- the present invention relates to a method for producing a drug for preventing or treating vascular wall thickening.
- a lower alkyl group means a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a terbutyl group, a pentyl group, an isopentyl group, a neopentyl group, tert-A straight-chain or branched alkynol having 1 to 6 carbon atoms such as a pentyl group, a hexyl group, etc.
- the hydroxy lower alkyl group refers to the lower alkyl group substituted with a hydroxyl group such as a 2-hydroxyethyl group, a 3-hydroxypropyl group, a 2-hydroxypropyl group, and a 4-hydroxybutyl group.
- amino lower alkyl group means the above lower alkyl group substituted by an amino group such as a 2-aminoethyl group, a 3-aminopropyl group, a 2-aminopropyl group or a 4-aminobutyl group.
- the aryl lower alkyl group refers to the lower alkyl group substituted with an aromatic hydrocarbon group such as a phenyl group or a naphthyl group. Examples thereof include a benzyl group, a phenyl group, a 3-phenylpropyl group, and a 2-phenylpropyl group. Groups and the like.
- Hydroxyaryl lower alkyl groups include 2-hydroxybenzyl group, 3-hydroxybenzyl group, 4-hydroxybenzyl group, 2-hydroxyphenyl group, 3-hydroxyphenyl group, and 4-hydroxyphenyl group. Butyl, 3- (2-hydroxyphenyl) propyl, 3- (3-hydroxyphenyl) propyl, 3- (4-hydroxyphenyl) propyl, 2- (2-hydroxyphenyl) propyl , 2— (3-hydroxyphenyl) propyl group, 2— (4 —Hydroxyphenyl)
- the aryl lower alkyl group in which an aryl moiety such as a propyl group is substituted with a hydroxyl group.
- the cycloalkyl group optionally having one or more oxygen atoms in the ring is a 3- to 7-membered cyclic alkyl group such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a cycloalkyl group.
- 4 to 7 having one or more oxygen atoms in a ring such as —tetrahydroviranyl group, 3-tetrahydroviranyl group, 4—tetrahydropyranyl group, 2-tetrahydrofuranyl group, 3—tetrahydrofuranyl group
- Member ring ⁇ ! Dog refers to an alkyl group.
- Lower alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, t ⁇ rt-butoxy, pentyloxy, isopentyloxy, neopentyl A straight-chain or branched alkoxy group having 1 to 6 carbon atoms such as a oxy group, a ter-pentyloxy group, a hexyloxy group and the like.
- Lower alkoxyaryl lower alkyl group means 2-methoxybenzyl group, 2-ethoxybenzyl group, 3-methoxybenzyl group, 3-ethoxybenzyl group, 4-methoxybenzyl group, 4-ethoxybenzyl group, 2 —Methoxyphenethyl group, 2 —Ethoxyphenethyl group, 3 —Methoxyphenethyl group, 3 _Ethoxyphenethyl group, 4-Methoxyphenethyl group, 4-Ethoxyphenethyl group, 3- (2-Methoxyphenyl) propyl group, 3 _ (2-ethoxyphenyl) propyl group, 3- (3-methoxyphenyl) propyl group, 3- (3-ethoxyphenyl) propyl group, 3- (4-methoxyphenyl) propyl Group, 3- (4-ethoxyphenyl) propyl group, 2- (2-methoxyphenyl) propyl group, 2- (2-ethoxyphen
- the hydroxy lower alkoxy group refers to the above-mentioned substituted with a hydroxyl group such as 2-hydroxyethoxy group, 3-hydroxypropoxy group, and 2-hydroxypropoxy group. Refers to a lower alkoxy group.
- the aryl lower alkoxy group refers to the lower alkoxy group substituted with the aromatic hydrocarbon group such as a benzyloxy group, a phenethyloxy group, a 3-phenylpropoxy group, and a 2-phenylpropoxy group.
- the cycloalkyl lower alkoxy group means the lower alkoxy group substituted with the cycloalkyl group such as cyclopentyl methoxy group, 2-cyclopentyl ethoxy group, cyclohexyl methoxy group, 2-cyclohexyl ethoxy group.
- a mono- or di-lower alkoxy lower alkyl group is a methoxymethyl group, an ethoxymethyl group, a 2-methoxyl group, a 2-ethoxyl group, a 3-methoxypropyl group, a 3-ethoxypropyl group, or a 1-methoxyl 2 —
- the lower being mono- or di-substituted by the lower alkoxy group such as propyl group, 1,3-dimethoxy-12-propyl group, 1-ethoxy-12-propyl group, 1,3-ethoxy-2-propyl group Refers to an alkyl group.
- Lower alkoxycarbonyl group includes methoxycarbonyl group, ethoxycarbonyl group, methoxycarbonyl group, isopropoxycarbonyl group, butoxycarbonyl group, isobutoxycarbonyl group, sec_butoxycarbonyl group, tert-butoxycarbonyl group.
- Mono or dihydroxy lower alkoxycarbonyl group means the lower alkoxycarbonyl group substituted by one or two hydroxyl groups (provided that two or more oxygen atoms are bonded to the same carbon atom) ), For example, 2-hydroxyethoxycarbonyl group, 3-hydroxypropoxycarbonyl group, 1-hydroxy-12-propoxycarbonyl group, 1,3-dihydroxy-12-propoxycarbonyl group and the like. it can.
- the mono- or di-lower alkoxy lower alkoxy carbonyl group means the lower alkoxy group substituted by one or two lower alkoxy groups.
- the hydroxyaryl lower alkoxycarbonyl group refers to the above-mentioned lower alkoxycarbonyl group substituted by a hydroxyaryl group such as a 2-hydroxyphenyl group, a 3-hydroxyphenyl group, or a 4-hydroxyphenyl group.
- Lower alkoxyaryl lower alkoxycarbonyl group means 2-methoxyphenyl group, 3-methoxyphenyl group, 4-methoxyphenyl group, 2-ethoxyphenyl group, 3-ethoxyphenyl group, 4-ethoxyphenyl group.
- the lower alkoxycarbonyl group substituted with the aromatic hydrocarbon group substituted with the lower alkoxy group such as a group, for example, a 2-methoxybenzyloxycarboxy group, a 2-ethoxybenzyl group; Oxycarbonyl group, 3-methoxybenzyloxycarbonyl group, 3-ethoxybenzyloxycarbonyl group, 4-methoxybenzyloxycarbonyl group, 4-ethoxybenzyloxycarbonyl group, 2-methoxycarbonyl group Enethyloxycarbonyl group, 2-ethoxyphenethyloxycarbonyl group, 3-methoxyphenethyloxy group Cicarbonyl group, 3-ethoxyphenethyloxycarbonyl group, 4-methoxyphenethyloxycarbonyl group, 4-ethoxyphenethyloxycarbonyl group, 3- (2-methoxyphenyl) pro Poxycarbonyl group, 3- (2-ethoxyphenyl) propoxycarbonyl group, 3- (3-
- the cycloalkyloxycarbonyl group optionally having one or more oxygen atoms in the ring means a cycloalkyloxycarbonyl group in which the cycloalkyl moiety is as defined above, for example, cyclopropyl Oxycarbonyl group, cyclobutyloxycarbonyl group, cyclopentyloxycarbonyl group, cyclohexyloxycarbonyl group, 2-tetrahydroviranyloxycarbonyl group, 3-tetrahydroviranyloxycarbonyl group, 4 -Tetrahydrovinyloxycarbonyl group, 2-tetrahydrofuranyloxycarbonyl group, 3-tetrahydrofuranyloxycarbonyl group and the like.
- Halogen atom means fluorine atom, chlorine atom, bromine atom and iodine atom.
- the lower acetyl group refers to an alkylcarboxy group having 2 to 7 carbon atoms having a linear or branched alkyl group such as an acetyl group, a propionyl group, and a ptyryl group.
- the mono- or di-lower alkyl-substituted amino group means an amino group or a dimethylamino group mono-substituted with the above lower alkyl group such as a methylamino group, an ethylamino group, a propylamino group, a butylamino group, a acetylamino group, a dipropylamino group, an ethyl group. It refers to an amino group di-substituted with the same or different lower alkyl groups such as a methylamino group, a methylpropylamino group and an ethylpropylamino group.
- Mono- or di-lower alkyl-substituted amino-lower alkyl group means 2-methylaminoethyl group, 2-ethylaminoethyl group, 2-propylaminoethyl group, 2-butylaminoethyl group, 2-dimethylaminoethyl group, Getylaminoethyl, 2-dipropylaminoethyl, 2-ethylmethylaminoethyl, 3-methylaminopropyl, 3-ethylaminopropyl, 3-propylaminopropyl, 3-butylamino Propyl group, 3-dimethylaminopropyl
- a lower alkyl group substituted with the above-mentioned mono- or di-lower alkyl-substituted amino group such as a group, 3-ethylaminopropyl group, 3-dipropylaminopropyl group or 3-ethylmethylaminopropyl group
- the alicyclic amino group which may have an oxygen atom in the ring means a 5- to 7-membered alicyclic amino group (however, when a hydroxyl group is used as a substituent, the substitution position except for the 2-position) ), For example, a 1-pyrrolidinyl group, a piperidino group, a morpholino group and the like.
- the compound represented by the general formula (I) of the present invention can be produced, for example, as follows. That is, the general formula (I) of the present invention
- R 1 is a hydrogen atom, a halogen atom, a hydroxyl group having a protecting group, a lower alkyl group, a lower alkoxy group, a hydroxy lower alkoxy group having a protecting group, a cycloalkyl lower alkoxy group, an aryl lower alkoxy group
- R 2 and R 3 have the same meanings as above, and are a lower acyl group, a mono-lower alkyl-substituted amino group having a protective group, a di-lower alkyl-substituted amino group or a lower alkoxycarbonyl group.
- Carboxylic acid derivatives or reactive functional derivatives such as acid halides and active esters thereof, and the general formula (HI)
- one of P and Q is an amino group
- the other is a lower alkoxycarbonyl group, a mono- or dihydroxy-lower-alkoxycarbonyl group having a protecting group, a mono- or di-lower alkoxy-lower alkoxycarbonyl group
- a hydroxyaryl lower alkoxycarbonyl group having a group, a lower alkoxyaryl lower alkoxycarbonyl group or an oxygen atom in the ring R 11 is a lower alkyl group, an amino lower alkyl group having a protecting group, a mono lower alkyl substituted amino lower alkyl group having a protecting group, a di lower alkyl substituted amino lower alkyl group, a protecting group.
- R 11 and R 12 may be bonded to each other to have an oxygen atom in the ring, and a hydroxyl group having a protecting group as a substituent, a lower alkoxy group, a hydroxy group having a protecting group, a lower alkyl group or a lower alkoxy group.
- [A 0 and B 0 in the formula are either general formulas.
- R 2 , R 3 and R 1 G have the same meanings as described above), and the other is a lower alkoxycarbonyl group, a mono- or dihydroxy group having a protective group, a lower alkoxycarbonyl group, a mono- or Di-lower-alkoxy lower-alkoxy force carbonyl group, hydroxyaryl-lower-alkoxycarbonyl group having a protecting group, lower-alkoxyaryl-lower-alkoxycarbonyl group or oxygen atom in the ring
- R 6 is a lower alkyl group such as a methyl group or an ethyl group.
- an imidazole dicarboxylic acid derivative represented by the general formula:
- the compounds represented by the general formulas (II) and (V) used as raw materials in the production method may be purchased as a commercial product, or may be produced by a known method described in a literature or a method similar thereto. it can.
- the compound represented by the general formula (III) used as a raw material in the above-mentioned production method can be produced, for example, by a known method described in a literature or a method similar thereto (for example, Tetrahedron, 42). Vol. 10, No.
- the compound represented by the general formula (IV) used as a raw material in the production method is, for example, a reactive functional group such as a caesmic acid derivative represented by the general formula (II) or an acid halide or an active ester thereof.
- the rubonic acid derivative can be converted into a pharmacologically acceptable salt thereof by a conventional method.
- salts include acid addition salts with mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, methanesulfonic acid, benzenesulfonic acid, p-toluene Acids with organic acids such as sulfonic acid, propionic acid, citric acid, conodic acid, tartaric acid, fumaric acid, butyric acid, oxalic acid, malonic acid, maleic acid, lactic acid, malic acid, carbonic acid, glutamic acid, and aspartic acid Salts with inorganic bases such as addition salts, sodium salts and potassium salts can be mentioned.
- the compound represented by the general formula (I) of the present invention also includes a solvate with a pharmaceutically acceptable solvent such as hydrated ethanol.
- the compound of the present invention represented by the general formula (I) has an unsaturated bond and thus has two geometric isomers.
- the present invention relates to a cis-form (Z-form) compound and a trans-form (E-form) )).
- trans-form (E-form) compounds are preferred.
- a compound having an asymmetric carbon atom has two optical isomers of an R configuration and an S configuration. And mixtures of their optical isomers.
- the compound of the present invention represented by the above general formula (I) is a very potent vascular smooth muscle in a cell growth inhibition test of nV itro using thoracic aortic vascular smooth muscle cells of spontaneously hypertensive rats. It has a cell growth inhibitory action.
- the compounds of the present invention represented by the general formula (I) and their drugs Physiologically acceptable salts have excellent inhibitory activity on intimal cell hyperproliferation and are very useful compounds as vascular wall thickening inhibitors.
- the compounds represented by the general formula (I) of the present invention include, for example, restenosis of the coronary artery after PTCA, restenosis after DCA, restenosis after placement of a stent in a blood vessel, autologous blood vessel and artificial blood vessel transplantation. It is effective in preventing or treating diseases caused by intimal cell hyperproliferation such as vascular wall thickening after organ transplantation, vascular wall thickening after organ transplantation, and arteriosclerosis.
- the compound of the present invention represented by the above general formula (I) showed a high drug concentration in plasma in an oral administration test to mice.
- the compound represented by the above general formula (I) and the pharmacologically acceptable salt thereof of the present invention are excellent compounds having good drug use efficiency.
- the compound represented by the general formula (I) of the present invention is a highly safe compound, and is an excellent compound having high utility S as a vascular wall thickening inhibitor.
- an appropriate pharmaceutical composition for example, It is administered orally or parenterally as tablets, powders, granules, capsules, injections and the like.
- These pharmaceutical compositions can be prepared by pharmaceutical methods used in general preparations, by using carriers, excipients and other additives commonly used for pharmaceuticals.
- the dose should be appropriately determined according to the gender, age, weight, and degree of symptoms of the target patient, and in the case of oral administration, it should be approximately 0.1 to 100 mg per adult per day. In the case of oral administration, the dose is generally in the range of 0.01 to 10 mg / day for adults, in single or divided doses. [Best Mode for Carrying Out the Invention]
- N, N-dimethylformamide (0.1 ml) was added to a solution of 3,4,5-trimethoxycinnamic acid (10.0 g) and thionyl chloride (6.1 ml) in toluene (100 ml), and the mixture was stirred at 80 ° C for 3 hours. did. The reaction mixture was concentrated under reduced pressure, and the residue was washed with hexane.
- a 1 cm square aluminum foil (2.07 g) was added to a solution of mercuric chloride (829 mg) in water (83 ml), and the mixture was stirred at room temperature for 1 minute. The water was removed by decantation, and the aluminum amalgam was washed with water, methanol and getyl ether in the same manner. Under an argon atmosphere, a solution of dimethyl ether (59 ml) and isopropyl hydroxyiminocyanoacetate (10 g) in dimethyl ether (42 ml) was added to the obtained aluminum amalgam, and water (4.2 ml) was added dropwise under ice cooling. And heated to reflux for 30 minutes.
- 3-Methoxypropyl hydroxyiminocyanoacetate (2.85 g) was added to water (20 ml), and saturated aqueous sodium hydrogen carbonate (16 ml) and sodium hydrosulfite (6.73 g) were added. Stirred for hours. An excessive amount of sodium chloride was added to the reaction mixture, and the mixture was sequentially extracted with methylene chloride and ethyl acetate, dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. Ethanol (20 ml) and ethoxyiminoacetate (1.91 g) were added to the obtained residue, and the mixture was heated under reflux for 1 day and then stirred at room temperature for 19 hours.
- the pyridinium chromate chromate (21.80 g) was suspended in methylene chloride (150 ml), sodium acetate (2.49 g) was added thereto, and the mixture was stirred at room temperature for 5 minutes.
- a solution of 1,3-diethoxy-1-propanol (3.00 g) in methylene chloride (50 ml) was added dropwise, and the mixture was stirred at room temperature for 2 days. After the solvent was distilled off under reduced pressure, Celite (registered trademark) (5 g) and getyl ether (100 ml) were added to the obtained residue.
- This mixture was purified by silica gel column chromatography (elution solvent: ethyl ether) to obtain 1,3-diethoxy-12-propanone (2.90 g).
- 1,3-Jetoxy 2-propanone-oxime (3.09 g) was dissolved in ethanol (40 ml), and 10% palladium on carbon (570 mg) was added thereto. After stirring at 90 ° C. and 5 atm under a hydrogen stream for 2 days, the reaction mixture was filtered through Celite (registered trademark), and the insolubles were washed with gethyruether. The filtrate is concentrated under reduced pressure to give 2-amino-1,
- S HR Spontaneously hypertensive rats
- the radioactivity incorporated into the DNA fraction was measured and used as an index of the cell growth activity of the test compound.
- the growth inhibitory activity of the test compound was represented by a concentration (IC 50 ) showing 50 % inhibition with respect to the untreated group (the DMEM culture solution added group containing no test compound). The results are shown in the table below.
- mice Male ICR mice were fasted for 4 hours, and test compounds suspended in 0.5% sodium carboxymethylcellulose were orally administered at a dose of 30 mgZkg. Blood was collected from the vein 30 minutes, 1, 2 and 4 hours after administration. After centrifuging the blood and separating the plasma, the plasma concentration of the test compound was measured using high performance liquid chromatography. The results are shown in the table below. The plasma concentration of the compound was represented by the maximum plasma concentration (gZml).
- mice Male 7-week-old ICR mice were fasted for 4 hours in groups of 5 mice, and suspended in 0.5% sodium carboxymethylcellulose (E) -12-ethylcarbamoyl -5 (4) I (3,4,5-trimethoxycinnamoylamino) imidazole 1 4 (5) Oral administration of monoethyl rubonate at a dose of 100, 300 or 100 Omg / kg . As a result, no deaths were observed in any of the administration groups, and no abnormalities occurred.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU67484/98A AU6748498A (en) | 1997-04-15 | 1998-04-10 | 2-substituted carbamoylimidazolecarboxylic acid derivatives and vascular-wall thickening inhibitor |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13274297 | 1997-04-15 | ||
JP9/132742 | 1997-04-15 | ||
JP9/273227 | 1997-08-28 | ||
JP27322797 | 1997-08-28 | ||
JP27322697 | 1997-08-28 | ||
JP9/273226 | 1997-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998046573A1 true WO1998046573A1 (fr) | 1998-10-22 |
Family
ID=27316572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/001655 WO1998046573A1 (fr) | 1997-04-15 | 1998-04-10 | Derives d'acide 2-substitue carbamoylimidazolecarboxylique et inhibiteur de l'epaississement de la paroi vasculaire |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6748498A (fr) |
WO (1) | WO1998046573A1 (fr) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997031900A1 (fr) * | 1996-02-29 | 1997-09-04 | Kissei Pharmaceutical Co., Ltd. | Derives d'imidazole et inhibiteur d'epaississement de la paroi vasculaire |
-
1998
- 1998-04-10 AU AU67484/98A patent/AU6748498A/en not_active Abandoned
- 1998-04-10 WO PCT/JP1998/001655 patent/WO1998046573A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997031900A1 (fr) * | 1996-02-29 | 1997-09-04 | Kissei Pharmaceutical Co., Ltd. | Derives d'imidazole et inhibiteur d'epaississement de la paroi vasculaire |
Also Published As
Publication number | Publication date |
---|---|
AU6748498A (en) | 1998-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI254045B (en) | 1,4-Benzothiazepine-1,1-dioxide derivatives substituted by sugar residues, for their preparation, pharmaceuticals comprising these compounds, and their use | |
TW200461B (fr) | ||
KR100837420B1 (ko) | 5-히드록시-인돌-3-카르복시산에스테르 유도체 및 이의용도 | |
WO2018196805A1 (fr) | Polymorphe de composé, procédé de préparation s'y rapportant et utilisation de celui-ci | |
CN110256421A (zh) | Kras-g12c抑制剂 | |
JPH07501330A (ja) | 新規な置換されたサリチル酸 | |
EP1902054B1 (fr) | Derives de pyrido[2,3-d]pyrimidine, leur preparation, leur application en therapeutique | |
WO2001068607A1 (fr) | Composes d'amide et utilisation | |
CN109928972B (zh) | 一种苦参碱衍生物及其在药物中的应用 | |
JP2020525409A (ja) | 置換アリールエーテル系化合物、その調製方法、医薬組成物およびその応用 | |
JP2016145212A (ja) | Cddoエチルエステルの多形体及びその用途 | |
WO2014127722A1 (fr) | Dérivé de dihydroartémisinine substituée par hétérocycle contenant de l'azote et son utilisation | |
JP2014534208A5 (fr) | ||
CN114380864B (zh) | 一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用 | |
WO1997026242A1 (fr) | Derives de 3-(bis-phenylmethylene substitue) oxindole | |
WO1997009301A1 (fr) | Derives de 2-acylaminobenzamide, preventif et remede contre des maladies causees par une surmultiplication des cellules vasculaires de l'intima | |
WO1997031900A1 (fr) | Derives d'imidazole et inhibiteur d'epaississement de la paroi vasculaire | |
WO1997002245A1 (fr) | Derives de benzamidoxime et leur utilisation a des fins medicinales | |
WO2019200502A1 (fr) | Forme cristalline de mésylate d'abémaciclib, procédé de préparation et composition pharmaceutique associés | |
WO1998046573A1 (fr) | Derives d'acide 2-substitue carbamoylimidazolecarboxylique et inhibiteur de l'epaississement de la paroi vasculaire | |
JP3621463B2 (ja) | カルボスチリル誘導体ビスマス塩 | |
CN115974855A (zh) | Ezh2和hdac双靶点抑制剂、其药物组合物及其制备方法和用途 | |
WO2006095922A1 (fr) | Compose de la tetrahydroisoquinoline et usage medical de ce compose | |
JP2007332061A (ja) | 新規ピラゾロ[1,5−a]ピリミジン誘導体及びその用途 | |
WO1999002527A1 (fr) | Derives de naphthyridine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GM GW HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09402489 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |